Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Summary by Business Wire

2 months ago

News Articles

More Filters

All

Left

Center

Right

Business Wire

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

2 months ago·Crystal River, United States

Read Full Article

incyte.com

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

– Villaris shareholders to receive upfront payment of $70 million , with potential for up to $1.36 billion in additional milestone payments – Pre-clinical data for auremolimab demonstrate high potency, selectivity and efficacy in vitiligo – Acquisition will complement Incyte’s existing Inflammation

2 months ago

Read Full Article

Bias Distribution

No sources with tracked biases.

See less detail

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

News Articles

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Similar News Topics

Bias Distribution

Similar News Topics

Time & Location

News Coverage Details

Bias Distribution

Similar News Topics

Bias Distribution